ERCC1: Impact in multimodality treatment of upper gastrointestinal cancer

Future Oncology

Volumn 6, Issue 11, 2010, Pages 1735-1749

  Metzger, Ralf ^a   Bollschweiler, Elfriede ^a   Hlscher, Arnulf H ^a   Warnecke Eberz, Ute ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

adenocarcinoma; ERCC1; esophageal cancer; gastric cancer; neoadjuvant chemoradiation; nucleotide excision repair; response; squamous cell carcinoma; upper GI cancer

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIRUBICIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MESSENGER RNA; OLAPARIB; OXALIPLATIN;

ADJUVANT THERAPY; CANCER RISK; DNA DAMAGE; ESOPHAGUS CANCER; EXCISION REPAIR; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MULTIMODALITY CANCER THERAPY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIATION; RADIATION DOSE; RELIABILITY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; VALIDITY;

COMBINED MODALITY THERAPY; DNA DAMAGE; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROGNOSIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 78650192007     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.140     Document Type: Review

References (119)

1. Bollschweiler E, Breckheimer S, Mönig SP, Hölscher AH: The prognostic relevance of age and comorbidity in patients with resected gastric cancer. Zentralbl. Chir. 134, 71-76 (2009).
2. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol. 2, 533-543 (2001).
3. Bollschweiler E, Wolfgarten E, Gutschow C, Hölscher AH: Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer. 92, 549-555 (2001).
4. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J: Australasian GastroIntestinal Trials Group: survival benefts from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 8, 226-234 (2007).
5. Bollschweiler E, Hölscher AH, Metzger R: Histologic tumor type and the rate of complete response after neoadjuvant therapy for esophageal cancer. Future Oncol. 6, 25-35 (2010).
6. Schneider PM, Baldus SE, Metzger R et al.: Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classifcation. Ann. Surg. 242, 684-692 (2005).
7. Metzger R, Leichman CG, Danenberg KD et al.: ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fuorouracil chemotherapy. J. Clin. Oncol. 16, 309-316 (1998).
8. Napieralski R, Ott K, Kremer M et al.: Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients. Clin. Cancer Res. 11, 3025-3031 (2005).
9. Rabik CA, Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev. 33, 9-23 (2007).
10. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22, 7265-7279 (2003).
11. Park DJ, Lenz HJ: Determinants of chemosensitivity in gastric cancer. Curr .Opin. Pharmacol. 6, 337-344 (2006).
12. Madhusudan S, Middleton MR: The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. Cancer Treat. Rev. 31, 603-617 (2005).
13. Gossage L, Madhusudan S: Cancer pharmacogenomics: role of DNA repair genetic polymorphisms in individualizing cancer therapy. Mol. Diagn. Ther. 11, 361-380 (2007).
14. Harper JW, Elledge SJ: The damage response: ten years after. Mol. Cell 28, 739-745 (2007).
15. Matsuoka S, Ballif BA, Smogorzewska A et al.: ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316, 1160-1166 (2007).
16. Martin LP, Hamilto TC, Schilder RJ: Platinum resistance: the role of DNA repair pathways. Clin. Canc. Res. 14, 1219-1295 (2008).
17. Shahzad MMK, Lopez-Berestein G, Sood AK: Novel strategies for reversing platinum resistance. Drug Resist. Updat. 12, 148-152 (2009).
18. Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC: Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res. 63, 1311-1316 (2003).
19. Ferry KV, Hamilton TC, Johnson SW: Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem. Pharmacol. 60, 1305-1313 (2000).
20. Fink D, Nebel S, Aebi S: The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 56, 4881-4886 (1996). (Pubitemid 26374423)
21. Raymond E, Chaney SG, Taamma A, Cvitkovic E: Oxalipatin: a review of preclinical and clinical studies. Ann. Oncol. 9, 1251-1253 (1998).
22. Rottenberg S, Jaspers JE, Kersbergen A et al.: High sensitivity of BRCA1-defcient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl Acad. Sci. USA 105, 17079-17084 (2008).
23. Fong PC, Boss DS, Yap TA et al.: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123-134 (2009).
24. Hagan M, Yacoub A, Dent P: Ionizing radiation causes a dose-dependent release of transforming growth factor a in vitro from irradiated xenografts and during palliative treatment of hormone-refractory prostate carcinoma. Clin. Canc. Res. 10, 5724-5731 (2004).
25. Lindahl T: Instability and decay of the primary structure of DNA. Nature 36, 709-715 (1993).
26. Sander M, Cadet J, Casciano DA et al.: Proceedings of a workshop on DNA adducts: biological signifcance and applications to risk assessment. Toxicol. Appl. Pharmacol. 208, 1-20 (2005).
27. Fridman AS, Galyuk EN, Vorob'ev VI, Skvortsov AN, Lando DY: Melting of crosslinked DNA: VI. Comparison of infuence of interstrand crosslinks and other chemical modifcations formed by antitumor compounds on DNA stability. J. Biomol. Struct. Dyn. 26, 175-185 (2008).
28. Brooks PJ: The 8,5́-cyclopurine-2́-deoxynucleosides: candidate neurodegenerative DNA lesions in xeroderma pigmentosum, and unique probes of transcription and nucleotide excision repair. DNA Repair 7, 1168-1179 (2008).
29. Cleaver JE: Cancer in xeroderma pigmentosum and related disorders of DNA repair. Nat. Rev. 5, 564-573 (2005).
30. Andressoo JO, Hoeijmakers JH et al.: Transcription-coupled repair and premature ageing. Mutat. Res. 577, 179-194 (2005).
31. Kraemer KH, Patronas NJ, Schiffman R, Brooks BP, Tamura D, Digiovanna JJ: Xeroderma pigmentosum, trichothiodystrophy and Cockayne syndrome: a complex genotype-phenotype relationship. Neuroscience 145, 1388-1396 (2007).
32. Cleaver JE, Thompson LH, Richardson AS, States JC: A summary of mutations in the UV-sensitive disorders: xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy. Human Mutat. 14, 9-22 (1999).
33. Houtsmuller AB, Rademakers S, Nigg AL, Hoogstraten D, Hoeijmakers JHJ, Vermeulen W: Action of RNA repair endonuclease ERCC1/XPF in living cells. Science 284, 958-961 (1995).
34. Hoeijmakers JHJ: Molecular origins of cancer: DNA damage, aging, and cancer. N. Engl. J. Med. 361, 1475-1485 (2009).
35. Gillet LC, Scharer OD: Molecular mechanisms of mammalian global genome nucleotide excision repair. Chem. Rev. 106, 253-276 (2006).
36. Fousteri M, Mullenders LH: Transcription-coupled nucleotide excision repair in mammalian cells: molecular mechanisms and biological effects. Cell Res. 18, 72-84 (2008).
37. Hanawalt PC: Subpathways of nucleotide excision repair and their regulation. Oncogene 21, 8949-8956 (2002).
38. Ogi T, Lehmann AR: The Y-family DNA polymerase k (pol k) functions in mammalian nucleotide excision repair. Nat. Cell Biol. 8, 640-642 (2006).
39. Moser J, Kool H, Giakzidis I, Caldecott K, Mullenders LH, Fousteri ML: Sealing of chromosomal DNA nicks during nucleotide excision repair requires XRCC1 and DNA ligase IIIa in a cell-cycle-specifc manner. Mol. Cell 27, 311-323 (2007).
40. Kamionka M, Feigon J: Structure of the XPC binding domain of hHR23A reveals hydrophobic patches for protein interaction. Protein Sci. 13, 1270-1277 (2004).
41. Yang A, Miron S, Mouawad L, Duchambon P, Blouquit Y, Craescu CT: Flexibility and plasticity of human centrin 2 binding to the xeroderma pigmewntosum group C protein (XPC) from nuclear excision repair. Biochemistry 45, 3654-3663 (2006).
42. Kim B, Ryu KS, Kim HJ, Cho SJ, Choi BS: Solution structure and backbone dynamics of the XPC-binding domain of the human DNA repair protein hHR23B Febs J. 272, 2467-2476 (2005).
43. Tsodikov OV, Enzlin JH, Scharer OD, Ellenberger T: Crystal structure and DNA binding functions of ERCC1, a subunit of the DNA structure-specifc endonclease XPF-ERCC1. Proc. Natl. Acad. Sci. 102, 11236-11241 (2005).
44. Tripsianes K, Folkers G, Ab E et al.: The structure of the human ERCC1/XPF interaction domains reveals a complementary role for the two proteins in nucleotide excision repair. Structure 13, 1849-1858 (2005).
45. Newman M, Murray-Rust J, Lally J et al.: Structure of an XPF endonuclease with and without DNA suggests a model for substrate recognition. EMBO J. 24, 895-905 (2005).
46. Fan L, Arvai AS, Cooper PK, Iwai S, Hanaoka F, Tainer JA: Conserved XPB core structure and motifs for DNA unvinding: implications for pathway selection of transcription or excision repair. Mol. Cell 22, 27-37 (2006).
47. Tsodikov OV, Ivanov D, Orelli B et al.: Structural basis for the recruitment of ERCC1-XPF to nucleotide excision repair complexes by XPA. EMBO J. 26, 4768-4776 (2007).
48. Gaillard PH, Wood RD: Activity of individual ERCC1 and XPF subunits in DNA nucleotide excision repair. Nucleic Acids Res. 29, 872-879 (2001).
49. de Laat WL, Sijbers AM, Odijk H, Jaspers NG, Hoeijmakers JH: Mapping of interaction domains between human repair proteins ERCC1 and XPF. Nucleic Acids Res. 26, 4146-4152 (1998).
50. Choi YJ, Ryu KS, Ko YM et al.: Biophysical characterization of the interaction domains and mapping of the contact residues in the XPF-ERCC1 complex. J. Biol. Chem. 280, 28644-28652 (2005).
51. Tripisianes K, Folkers GE, Zheng C et al.: Analysis of the XPA and ssDNA-binding surfaces on the central domain of human ERCC1 reveals evidence for subfunctionalization. Nucleic Acids Res. 35, 5789-5798 (2007).
52. Doherty AJ, Serpell LC, Ponting CP: The helix-hairpin-helix DNA-binding motif: a structural basis for non-sequence-specifc recognition of DNA. Nucleic Acids Res. 24, 2488-2497 (1996).
53. Kuraoka I, Kobertz WR, Ariza RR, Biggerstaff M, Essigmann JM, Wood RD: Repair of an interstrand DNA cross-link initiated by ERCC1-XOF repair/ recombination nuclease. J. Biol. Chem. 275, 26632-26636 (2000).
54. Niedernhofer LJ, Odijk H, Budzowska M et al.: The structure-specifc endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol. Cell Biol. 24, 5776-5787 (2004).
55. Zhu XD, Niedernhofer L, Kuster B, Mann M, Hoeijmakers JH, de Lange T: ERCC1/XPF removes the 3́ overhang from uncapped telomeres and represses formation of telomeric DNA-containing double minute chromosomes. Mol. Cell 12, 1489-1498 (2003).
56. Munoz P, Blanco R, Flores JM, Blasco MA: XPF nuclease-dependent telomere loss and increased DNA damage in mice overexpressing TRF2 result in premature aging and cancer. Nat. Genet. 37, 1063-1071 (2005).
57. Wu Y, Zacal NJ, Rainbow AJ, Zhu XD: XPF with mutations in its conserved nuclease domain is defective in DNA repair but functions in TRF2-mediated telomere shortening. DNA Repair 6, 157-166 (2007).
58. Li L, Elledge SJ, Peterson CA, Bales ES, Legerski RJ: Specifc association between the human DNA repair proteins XPA and ERCC1. Proc. Natl. Acad. Sci. 91, 5012-5016 (1994).
59. Rosenberg E, Taher MM, Kuemmerle NB, Farnsworth J, Valerie K: A truncated human xeroderma pigmentosum complementation group A protein expressed froman adenovirus sensitizes human tumor cells to ultraviolet light and cisplatin. Cancer Res. 61, 764-770 (2001).
60. Li L, Peterson CA, Lu X, Legerski RJ: Mutations in XPA that prevent association with ERCC1 are defective in nucleotide excision repair. Mol. Cell Biol. 15, 1993-1998 (1995).
61. Croteau DL, Peng Y, VanHouten B: DNA repair gets physical: mapping a XPA binding site on ERCC1. DNA Repair 7, 819-826 (2008).
62. Volker M, Mone MJ, Karmakar P et al.: Sequential assembly of the nucleotide excision repair factors in vivo. Mol. Cell. 8, 213-375 (2001).
63. Riedl T, Hanaoka F, Egly JM: The comings and goings of nucleotide excision repair factors on damaged DNA. EMBO J. 22, 5293-5303 (2003).
64. Orelli B, McClendon TB, Tsodikov OV, Ellenberger T, Niedernhofer LJ, Schärer OD: The XPA-binding domain of ERCC1 is required for nucleotide excision repair but not other DNA repair pathways. J. Biol. Chem. 285, 3705-3712 (2010).
65. Park CH, Bessho T, Matsunaga T, Sancar A: Purifcation and characterization of the XPF-ERCC1 complex of human DNA repair excision nuclease. J. Biol. Chem. 270, 22657-22660 (1995).
66. Altaha R, Liang X, Yu JJ, Reed E: Excision repair cross complementing-group 1: gene expression and platinum resistence. Int. J. Mol. Med. 14, 959-970 (2004).
67. Li Q, Ding L, Yu JJ et al.: Cisplatin and phorbol ester independently induce ERCC1 protein in human ovarian carcinoma cells. Int. J. Oncol. 14, 987-992 (1998).
68. Dabholkar MD, Berger MS, Vionnet JA et al.: Malignant and nonmalignant brain tissues differ in their messenger RNA expression patterns for ERCC1 and ERCC2. Cancer Res. 55, 1261-1266 (1995).
69. Friedberg EC: How nucleotide excision repair protects against cancer. Nat. Rev. Cancer 1, 22-33 (2001).
70. Cheng L, Sturgis EM, Eicher SA, Spitz MR, Wei Q: Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck. Cancer 94, 393-397 (2002). (Pubitemid 34081368)
71. Vogel U, Nexø BA, Tjønneland A, Wallin H, Hertel O, Raaschou-Nielsen O: ERCC1, XPD and RAI mRNA levels in lymphocytes are not associated with lung cancer risk in a prospective study of Danes. Mutat. Res. 593, 88-96 (2006).
72. Goode EL, Ulrich CM, Potter JD: Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol. Biomarkers Prev. 11, 1513-1530 (2002).
73. Mohrenweiser HW: Genetic variation and exposure related risk estimation: will toxicology enter a new era? DNA repair and cancer as a paradigm. Toxicol. Pathol 32(Suppl. 1), 136-145 (2004).
74. de Boer JG: Polymorphisms in DNA repair and environmental interactions. Mutat. Res. 509, 201-210 (2002).
75. Li Y, Gu S, Wu Q, Li Y, Fu X, Mao Y, Huang Y, Xie Y: No association of ERCC1 C8092A and T19007C polymorphisms to cancer risk: a meta-analysis. Eur. J. Hum. Genet. 15, 967-973 (2007). (Pubitemid 47308473)
76. Moreno V, Gemignani F, Landi S et al.: Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin. Cancer Res. 12, 2101-2108 (2006).
77. Vogel U, Laros I, Jacobsen NR et al.: Two regions in chromosome 19q13.2-3 are associated with risk of lung cancer. Mutat. Res. 546, 65-74 (2004).
78. Matullo G, Guarrera S, Sacerdote C et al.: Polymorphisms/haplotypes in DNA repair genes and smoking: a bladder cancer case-control study. Cancer Epidemiol. Biomarkers Prev. 14, 2569-2578 (2005).
79. Sturgis EM, Dahlstrom KR, Spitz MR, Wei Q: DNA repair gene ERCC1 and ERCC2/XPD polymorphisms and risk of squamous cell carcinoma of the head and neck. Arch. Otolaryngol. Head Neck Surg. 128, 1084-1088 (2002). (Pubitemid 35014604)
80. Kiyohara C, Yoshimasu K: Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis. Int. J. Med. Sci. 4, 59-71 (2007).
81. Matullo G, Dunning AM, Guarrera S et al.: DNA repair polymorphisms and cancer risk in non-smokers in a cohort study. Carcinogenesis 27, 997-1007 (2006).
82. Britten RA, Liu D, Tessier A, Hutchison MJ, Murray D: ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int. J. Cancer 89, 453-457 (2000).
83. Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E: ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J. Natl Cancer Inst. 84, 1512-1517 (1992).
84. Warnecke-Eberz U, Vallböhmer D, Alakus H et al.: ERCC1 and XRCC1 gene polymorphisms predict response to neoadjuvant radiochemotherapy in esophageal cancer. J. Gastrointest. Surg. 13, 1411-1421 (2009).
85. Brookes AJ: The essence of SNPs. Gene 234, 177-186 (1999).
86. Shen MR, Jones IM, Mohrenweiser H: Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res. 58, 604-608 (1998).
87. Chen P, Wiencke J, Aldape K et al.: Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol. Biomarkers Prev. 9(8), 843-847 (2000).
88. Yu JJ, Lee KB, Mu C, Li Q, Abernathy TV, Bostick-Bruton F, Reed E: Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int. J. Oncol. 16, 555-560 (2000).
89. Kim MK, Cho KJ, Kwon GY et al.: ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. Eur. J. Cancer 44, 54-60 (2008).
90. Kim MK, Cho KJ, Kwon GY et al.: Patients with ERCC1-negative locally advanced esophageal cancers may beneft from preoperative chemoradiotherapy. Clin. Cancer Res. 14, 4225-4231 (2008).
91. Fareed KR, Al-Attar A, Soomro IN et al.: Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy. Br. J. Cancer 102, 1600-1607 (2010).
92. Olaussen KA, Fouret P, Kroemer G: ERCC1-specifc immunostaining in non-small-cell lung cancer. N. Engl. J. Med. 357, 1559-1561 (2007).
93. Kwon HC, Roh MS, Oh SY et al.: Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fuorouracil/ oxaliplatin chemotherapy in advanced gastric cancer. Ann. Oncol. 18, 504-509 (2007).
94. Baek SK, Kim SY, Lee JJ, Kim Y W, Yoon HJ, Cho KS: Increased ERCC expression correlates with improved outcome of patients treated with cisplatin as an adjuvant therapy for curatively resected gastric cancer. Cancer Res. Treat. 38, 19-24 (2006).
95. Bamias A, Karina M, Papakostas P et al.: A randomized Phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemother. Pharmacol. 65, 1009-1021 (2010).
96. Kim JS, Kim MA, Kim TM et al.: Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fuorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival. Br. J. Cancer 100, 732-738 (2009).
97. Warnecke-Eberz U, Metzger R, Miyazono F et al.: High specifcity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin. Cancer Res. 10, 3794-3799 (2004).
98. Warnecke-Eberz U, Metzger R, Bollschweiler E et al.: TaqMan low-density arrays and analysis by artifcial neuronal networks predict response to neoadjuvant chemoradiation in esophageal cancer. Pharmacogenomics 11, 55-64 (2010).
99. Joshi MB, Shirota Y, Danenberg KD et al.: High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin. Cancer Res. 11, 2215-2221 (2005).
100. Brabender J, Vallböhmer D, Grimminger P et al.: ERCC1 RNA expression in peripheral blood predicts minor histopathological response to neoadjuvant radio-chemotherapy in patients with locally advanced cancer of the esophagus. J. Gastrointest. Surg. 12, 1815-1821 (2008).
101. Langer R, Specht K, Becker K et al.: Prediction of response to neoadjuvant chemotherapy in Barrett's carcinoma by quantitative gene expression analysis. Verh. Dtsch. Ges. Pathol. 88, 207-213 (2004).
102. Langer R, Specht K, Becker K et al.: Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma. Clin. Cancer Res. 11, 7462-7469 (2005).
103. Matsubara J, Nishina T, Yamada Y et al.: Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br. J. Cancer 98, 832-839 (2008).
104. Wei J, Zou Z, Qian X et al.: ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modifed FOLFOX regimen. Br. J. Cancer 98, 1398-1402 (2008).
105. Bradbury PA, Kulke MH, Heist RS et al.: Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenet. Genomics 19, 613-625 (2009).
106. Schneider S, Uchida K, Brabender J et al.: Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. J. Am. Coll. Surg. 200, 336-344 (2005).
107. Chang PM-H, Tzeng C-H, Chen P-M et al.: ERCC1 codon 118 C->T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma. Cancer Sci. 100, 279-283 (2009).
108. Huang ZH, Hua D, Du X et al.: ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer. World J. Gastroenterol. 14, 6401-6407 (2008).
109. Goekkurt E, Al-Batran SE, Hartmann JT et al.: Pharmacogenetic analyses of a Phase III trial in metastatic gastroesophageal adenocarcinoma with fuorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. J. Clin. Oncol. 27, 2863-2873 (2009).
110. Tse D, Zhai R, Zhou W et al.: Polymorphisms of the NER pathway genes, ERCC1 and XPD are associated with esophageal adenocarcinoma risk. Cancer Causes Control. 19, 1077-1083 (2008).
111. Doecke J, Zhao ZZ, Pandeya N et al.: Whiteman DC; Australian Cancer Study: Polymorphisms in MGMT and DNA repair genes and the risk of esophageal adenocarcinoma. Int. J. Cancer 123, 174-180 (2008).
112. Pan J, Lin J, Izzo JG et al.: Genetic susceptibility to esophageal cancer: the role of the nucleotide excision repair pathway. Carcinogenesis 30, 785-792 (2009).
113. Ma WJ, Lv GD, Zheng ST et al.: DNA polymorphism and risk of esophageal squamous cell carcinoma in a population of North Xinjiang, China. World J. Gastroenterol. 16, 641-647 (2010).
114. Ruzzo A, Graziano F, Kawakami K et al.: Pharmacogenetic profling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J. Clin. Oncol. 24, 1883-1891 (2006).
115. Ruzzo A, Canestrari E, Maltese P et al.: Polymorphisms in genes involved in DNA repair and metabolism of xenobiotics in individual susceptibility to sporadic diffuse gastric cancer. Clin. Chem. Lab. Med. 45, 822-828 (2007).
116. Seo BG, Kwon HC, Oh SY et al.: Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI. Oncol Rep. 22, 127-136 (2009).
117. Stocker G, Ott K, Henningsen N et al.: CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma. Eur. J. Cancer 45, 3326-3335 (2009).
118. Shim HJ, Yun JY, Hwang JE et al.: BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin. Cancer Sci. 101(5), 1247-1254 (2010).
119. Tanaka K, Otake K, Mohri Y et al.: Clinical signifcance of the gene expression profle in residual tumor cells after neoadjuvant chemo-radiotherapy for esophageal cancer. Oncol. Rep. 21, 1489-1494 (2009).